BI-1808 and pembrolizumab combination shows a 24% ORR in recurrent ovarian cancer, surpassing pembrolizumab monotherapy's 8% ...
The LARA trial (NCT04699071), a multi-center, single-arm, phase 2 study, found that combining pembrolizumab (Keytruda) with ...
In a significant shift for the treatment landscape of essential thrombocythemia (ET), the US National Comprehensive Cancer Network (NCCN) has designated ropeginterferon alfa-2b-njft (Besremi) as a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results